Author + information
- Received April 5, 2017
- Revision received August 23, 2017
- Accepted September 1, 2017
- Published online October 9, 2017.
- Carl J. Lavie, MDa,∗ (, )
- Ambarish Pandey, MDb,
- Dennis H. Lau, MBBS, PhDc,
- Martin A. Alpert, MDd and
- Prashanthan Sanders, MBBS, PhDc
- aDepartment of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, Louisiana
- bDivision of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas
- cCentre for Heart Rhythm Disorders, South Australian Health and Medical Research Institution, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia
- dDivision of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, Missouri
- ↵∗Address for correspondence:
Dr. Carl J. Lavie, Cardiac Rehabilitation, Exercise Laboratories, John Ochsner Heart and Vascular Institute, Ochsner Clinical School - The University of Queensland School of Medicine, 1514 Jefferson Highway, New Orleans, Louisiana 70121-2483.
Both obesity and atrial fibrillation (AF) are increasing in epidemic proportions, and both increase the prevalence of cardiovascular disease events. Obesity has adverse effects on cardiovascular hemodynamics and cardiac structure and function, and increases the prevalence of AF, partly related to electroanatomic remodeling in obese patients. However, numerous studies, including in AF, have demonstrated an obesity paradox, where overweight and obese patients with these disorders have a better prognosis than do leaner patients with the same degree of severity of cardiovascular disease/AF. In this paper, the authors discuss special issues regarding AF in obesity, as well as the evidence that despite the presence of an obesity paradox, there are benefits of weight loss, physical activity/exercise training, and increases in cardiorespiratory fitness on the prognosis of obese patients with AF.
Dr. Sanders is supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia. Dr. Lavie is author of the book The Obesity Paradox; and has served as a promotional speaker and consultant for Bristol-Myers Squibb, Pfizer, and Boehringer Ingelheim. Dr Lau has received lecture and/or consulting fees from St. Jude Medical, Boehringer Ingelheim, Bayer, and Pfizer. Dr. Sanders has been on advisory boards of Biosense Webster, Medtronic, St. Jude Medical, Boston Scientific, and CathRx; has received lecture and/or consulting fees from Biosense Webster, Medtronic, St. Jude Medical, and Boston Scientific; and has received research funding from Medtronic, St. Jude Medical, Boston Scientific, Biotronik, and Sorin. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received April 5, 2017.
- Revision received August 23, 2017.
- Accepted September 1, 2017.
- 2017 American College of Cardiology Foundation